DR. ELLIOT DANFORTH, M.D.
Osteopathic Medicine at Beartown Rd, Underhill Flats, VT
License number
Vermont 042-0004096
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
84 Beartown Rd, Underhill Flats, VT 05489
Phone
(802) 899-2349
Professional information
President At Beartownpharma, Inc.
Position:
President at BeartownPharma, Inc.
Location:
Burlington, Vermont Area
Industry:
Biotechnology
Work:
BeartownPharma, Inc.
- 84 Beartown Road, Underhill, VT 05489 since Dec 2000
-
President
Lederle Pharmaceutical Co.
Jul 1993 - Apr 1998
-
Executive Director Cardiovascular and Metabolic Diseases
University of Vermont College of Medicine
1970 - 1993
-
Professor Emeritus
Walter Reed Army Institute of Research
- Washington DC Jul 1966 - Jul 1970
-
Captain USAMC
Education:
Albany College of Medicine 1960 - 1964
"MD", Medicine Dartmouth College 1952 - 1956
"AB", Biochemistry and Molecular Biology
"MD", Medicine Dartmouth College 1952 - 1956
"AB", Biochemistry and Molecular Biology
Dr. Elliot Danforth, Underhill VT - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
BEARTOWN PHARMA, INC.
84 Beartown Rd, Underhill 05489
(802) 899-2349 (Phone), (802) 899-2349 (Fax)
84 Beartown Rd, Underhill 05489
(802) 899-2349 (Phone), (802) 899-2349 (Fax)
Certifications:
Internal Medicine, 1971
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Albany Medical College
Dartmouth Affil Hosps
Walter Reed Genl Hosp
Albany Medical College
Dartmouth Affil Hosps
Walter Reed Genl Hosp
Pharmaceutical Compositions Of Tetrac And Methods Of Use Thereof
US Patent:
2004022, Nov 4, 2004
Filed:
Nov 17, 2003
Appl. No.:
10/715586
Inventors:
Elliot Danforth - Underhill VT, US
Albert Burger - Geneva, CH
Albert Burger - Geneva, CH
Assignee:
BeartownPharma, Inc.
International Classification:
A61K031/195
US Classification:
514/567000
Abstract:
The present invention provides novel pharmaceutical compositions and methods of treatment that utilize or comprise tetrac and/or another thyromimetic compound. The pharmaceutical compositions of the invention are capable of suppressing TSH secretion without inhibiting the pituitary specific monodeiodinase type II and while reducing or avoiding the thyromimetic stimulation of peripheral tissues compared to equivalent TSH-suppressive doses of L-thyroxine (T4). The pharmaceutical compositions of the invention are particularly useful for treating patients suffering from malignancy or abnormal growth of the thyroid and for preventing growth of residual thyroid tissue post thyroidectomy.